205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
Sara A. Hurvitz, Anne F. Schott, X. Cynthia, Rita Nanda, G. Zahrah, N. Hunter, Adrienne Tan, Melinda L. Telli, Jesús Anampa, R. Jeselsohn, Pamela N. Münster, Eric Zhi, R. Gedrich, C. Mather, Hyo S. Han, E.P. Hamilton
Abstract
The oral PROTAC protein degrader ARV-471 binds and degrades wild-type (WT) and mutant ER. The phase II expansion (VERITAC) of a phase I/II study (NCT04072952) tested 2 ARV-471 doses (200 mg once daily [QD] and 500 mg QD) in heavily pretreated patients (pts) with ER+/HER2- advanced breast cancer. ARV-471 200 mg QD was selected as the phase III monotherapy dose based on comparable efficacy and favorable tolerability vs 500 mg QD and robust ER degradation (data cutoff: Jun 6, 2022). We present updated data for ARV-471 200 mg QD after 5 additional months of follow-up.